Treatment Group # of Mice # of Tumors Tumor Volume, mm3 (Mean ± SEM) T-test P-Value (vs Control ) Normalized Tumor Volume (Mean ± SEM) T-test P-Value vs Control Day 1 Day 7 Day 14 Day 1 Day 7 Day 14 Day 7 Day 14 Day 7 Day 14 A. Control 38 65 675 ± 60  750 ± 64 1095 ± 102 — — — 1.22 ± 0.06 1.86 ± 0.19 — —                                               B. WHI-P131[NP] 17 38 1004 ± 98  755 ± 89 666 ± 86 0.006 0.969 0.002 0.77 ± 0.04 0.70 ± 0.06 7.5x10-9 1.5x10-7                                               C. Chemo 81 116 518 ± 32 635 ± 39 748 ± 46 0.023 0.125 0.003 1.30 ± 0.05 1.57 ± 0.07 0.266 0.155                                                 C.1 Taxol 27 41 526 ± 51 673 ± 57 788 ± 71 0.059 0.366 0.015 1.47 ± 0.10 1.72 ± 0.12 0.033 0.516   C.2 Gemcitabine 34 47 563 ± 59 690 ± 72 803 ± 81 0.184 0.531 0.027 1.26 ± 0.09 1.58 ± 0.12 0.634 0.211   C.3 Gefinitib 20 28 433 ± 47 487 ± 62 599 ± 83 0.002 0.004 3.0x10-4 1.12 ± 0.08 1.35 ± 0.11 0.351 0.020

Table 1: Anti-Cancer Activity of WHI-P131 Nanoparticles in the MMTV/Neu Transgenic Mouse Model of Metastatic HER2+ Breast Cancer. WHI-P131 [NP] (100mg/kg or 150 mg/kg) was administered i.p. daily for 5 consecutive days each week, x 2 weeks; Taxol (6.7 mg/kg) was administered i.p. on days 1,3, and 5; Gemcitabine (33.7 mg/kg) was administered i.p on days 1 and 8; Gefi nitib (75 mg/kg) was administered daily by gavage. Control group included mice that were treated with i.p. injections of WHI-P131-free vehicle, WHI-P131 [NP] at the ineffective 50 mg/kg dose level, or PBS.